(NASDAQ: FLGT) Fulgent Genetics's forecast annual revenue growth rate of 7.24% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 6.06%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.56%.
Fulgent Genetics's revenue in 2026 is $330,275,000.On average, 3 Wall Street analysts forecast FLGT's revenue for 2026 to be $9,549,550,200, with the lowest FLGT revenue forecast at $9,175,167,600, and the highest FLGT revenue forecast at $9,830,616,540. On average, 3 Wall Street analysts forecast FLGT's revenue for 2027 to be $10,470,140,250, with the lowest FLGT revenue forecast at $10,059,436,950, and the highest FLGT revenue forecast at $10,778,028,030.
In 2028, FLGT is forecast to generate $11,796,963,360 in revenue, with the lowest revenue forecast at $10,590,557,340 and the highest revenue forecast at $12,940,786,020.